利鲁唑
化学
替莫唑胺
同步加速器
细胞培养
癌症研究
细胞
胶质母细胞瘤
病理
生物化学
医学
生物
受体
核物理学
物理
谷氨酸受体
遗传学
作者
Tanja Dučić,Milena Ninković,Immaculada Martínez‐Rovira,Swetlana Sperling,Veit Rohde,Dragoljub Dimitrijević,G. Jover-Mañas,Lisa Vaccari,Giovanni Birarda,Ibraheem Yousef
标识
DOI:10.1021/acs.analchem.1c02076
摘要
Glioblastoma multiforme (GBM) is the most aggressive brain tumor, characterized by short median survival and an almost 100% tumor-related mortality. The standard of care treatment for newly diagnosed GBM includes surgical resection followed by concomitant radiochemotherapy. The prevention of disease progression fails due to the poor therapeutic effect caused by the great molecular heterogeneity of this tumor. Previously, we exploited synchrotron radiation-based soft X-ray tomography and hard X-ray fluorescence for elemental microimaging of the shock-frozen GBM cells. The present study focuses instead on the biochemical profiling of live GBM cells and provides new insight into tumor heterogenicity. We studied bio-macromolecular changes by exploring the live-cell synchrotron-based Fourier transform infrared (SR-FTIR) microspectroscopy in a set of three GBM cell lines, including the patient-derived glioblastoma cell line, before and after riluzole treatment, a medicament with potential anticancer properties. SR-FTIR microspectroscopy shows that GBM live cells of different origins recruit different organic compounds. The riluzole treatment of all GBM cell lines mainly affected carbohydrate metabolism and the DNA structure. Lipid structures and protein secondary conformation are affected as well by the riluzole treatment: cellular proteins assumed cross β-sheet conformation while parallel β-sheet conformation was less represented for all GBM cells. Moreover, we hope that a new live-cell approach for GBM simultaneous treatment and examination can be devised to target cancer cells more specifically, i.e., future therapies can develop more specific treatments according to the specific bio-macromolecular signature of each tumor type.
科研通智能强力驱动
Strongly Powered by AbleSci AI